Last reviewed · How we verify
HAM
HAM is a hematopoietic stem cell mobilization and collection system used to facilitate autologous stem cell transplantation.
HAM is a hematopoietic stem cell mobilization and collection system used to facilitate autologous stem cell transplantation. Used for Mobilization and collection of hematopoietic stem cells for autologous stem cell transplantation in hematologic malignancies, Support for high-dose chemotherapy with stem cell rescue.
At a glance
| Generic name | HAM |
|---|---|
| Sponsor | DKMS gemeinnützige GmbH |
| Modality | Small molecule |
| Therapeutic area | Oncology/Hematology |
| Phase | FDA-approved |
Mechanism of action
HAM (Haematopoietic stem cell Apheresis and Mobilization) is a marketed medical device/procedure system developed by DKMS for mobilizing and collecting hematopoietic stem cells from patients or donors. It is used in the context of autologous stem cell transplantation for hematologic malignancies and other conditions requiring stem cell rescue.
Approved indications
- Mobilization and collection of hematopoietic stem cells for autologous stem cell transplantation in hematologic malignancies
- Support for high-dose chemotherapy with stem cell rescue
Common side effects
Key clinical trials
- SUBDIMA: Subclinical Depression in Acute Myocardial Infarction (SUBDIMA25) (NA)
- A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML (PHASE2)
- Air-Dried Human Amniotic Membrane Terminally Sterilized by Gamma Irradiation for Multidisciplinary Clinical Application (PHASE1)
- Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (PHASE1, PHASE2)
- IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. (PHASE3)
- Evaluation of Patients With HAM/TSP
- Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders (NA)
- Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HAM CI brief — competitive landscape report
- HAM updates RSS · CI watch RSS
- DKMS gemeinnützige GmbH portfolio CI